Phanes Therapeutics Announces FDA IND Clearance for PT217, an Anti-DLL3/Anti-CD47 Bispecific Antibody Being Developed for Patients With Small Cell Lung Cancer and Other Neuroendocrine Cancers

The Phase I study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of PT217 in subjects with advanced or refractory cancers. Patients with the following tumor types will be eligible for screening: unresectable small cell lung cancer, large cell neuroendocrine cancer, neuroendocrine prostate cancer, and gastroenteropancreatic neuroendocrine tumors.